Clincosm LogoSign in Get a demo

cin1

Showing 1 - 11 of 11
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Papilloma Viral Infection, CIN1, LSIL, Low Grade Squamous Intraepithelial Lesion Trial in Madrid (Glizigen, Placebo)

Recruiting
  • Papilloma Viral Infection
  • +2 more
  • Glizigen
  • Placebo
  • Madrid, Spain
  • +3 more
Jun 27, 2023

HPV Infection, CIN1 Trial in Belgium, Estonia, United Kingdom (ChAdOx1-HPV, MVA-HPV, Placebo)

Active, not recruiting
  • HPV Infection
  • CIN1
  • ChAdOx1-HPV
  • +2 more
  • Antwerp, Belgium
  • +15 more
Jan 9, 2023

Cervical Cancer, Genital Wart, CIN1 Trial (Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine

Not yet recruiting
  • Cervical Cancer
  • +11 more
  • Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)
  • Placebo
  • (no location specified)
Oct 17, 2022

HPV Infections, Cervical Cancer, Vulvar Cancer Trial in Guangxi (Experimental: Experimental: 9-valent Human Papillomavirus

Completed
  • HPV Infections
  • +14 more
  • Experimental: Experimental: 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)
  • Active Comparator: GARDASIL ®9
  • Guangxi, China
    Guangxi Zhuang Autonomous Region Center for Disease Control and
May 9, 2022

After Whole Vaccination Shcedule With Recombination Quadrivalent

Not yet recruiting
  • HPV Infections
  • +6 more
    • (no location specified)
    May 7, 2022

    HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer Trial in Mianyang (2-doses Group among 9-14 years, 3-doses Group among

    Recruiting
    • HPV Infections
    • +6 more
    • 2-doses Group among 9-14 years
    • +2 more
    • Mianyang, Sichuan, China
      Center for Disease Control and Prevention
    Feb 23, 2022

    HPV Infections, Cervical Cancer, Vulvar Cancer Trial in Hangzhou (9-valent HPV vaccine)

    Recruiting
    • HPV Infections
    • +14 more
    • 9-valent HPV vaccine
    • Hangzhou, China
      Huakun Lv
    Feb 23, 2022

    Cervical Cancer, Vulvar Cancer, Vaginal Cancer Trial in Yangchun (4-valent HPV Vaccine, 9-valent HPV Vaccine, GARDASIL®)

    Completed
    • Cervical Cancer
    • +13 more
    • 4-valent HPV Vaccine
    • +2 more
    • Yangchun, Guangdong, China
      Yangchun Center For Disease Prevention And Control
    Feb 23, 2022

    Cervical Cancer, Vulvar Cancer, Vaginal Cancer Trial in Rongan County (9-valent Human Papillomavirus (Types 6, 11, 16,

    Recruiting
    • Cervical Cancer
    • +13 more
    • 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
    • GARDASIL®
    • Rongan County, Guangxi Zhuang Autonomous Region, China
      Rongan County Center for Disease Control and Prevention
    Feb 20, 2022

    Human Papilloma Virus, Dysplasia, CIN1 Trial in Houston (AHCC 3 grams once a day, Placebo)

    Completed
    • Human Papilloma Virus
    • +3 more
    • AHCC 3 grams once a day
    • Placebo
    • Houston, Texas
      UTHealth Medical School at Houston
    Jan 15, 2021

    Cervical Cancers, Vulvar Cancer, Vaginal Cancer Trial in Hanzhou (9-valent HPV Recombinant Vaccine, Placebo)

    Completed
    • Cervical Cancers
    • +14 more
    • 9-valent HPV Recombinant Vaccine
    • Placebo
    • Hanzhou, China
      Zhejiang Provincial Center for Disease Control and Prevention
    Jan 20, 2020